Overview

TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Status:
Unknown status

Trial end date:
2017-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of tyrosine kinase inhibitor(TKI) therapy based on molecular monitoring of BCR/ABL levels in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)undergoing allogeneic hematopoietic stem cell transplantation(allo-HSCT).

Phase:

Phase 2

Details

Lead Sponsor:

Nanfang Hospital of Southern Medical University

Collaborators:

Guangdong Provincial People's Hospital
Guangxi Medical University
Guangzhou General Hospital of Guangzhou Military Command
Peking University People's Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Third Affiliated Hospital, Sun Yat-Sen University